These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 25581823

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
    Kodama T, Tsukaguchi T, Yoshida M, Kondoh O, Sakamoto H.
    Cancer Lett; 2014 Sep 01; 351(2):215-21. PubMed ID: 24887559
    [Abstract] [Full Text] [Related]

  • 5. Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
    Taniguchi H, Takeuchi S, Fukuda K, Nakagawa T, Arai S, Nanjo S, Yamada T, Yamaguchi H, Mukae H, Yano S.
    Cancer Sci; 2017 Jan 01; 108(1):53-60. PubMed ID: 27783866
    [Abstract] [Full Text] [Related]

  • 6. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G, Seto T.
    Respir Investig; 2014 Nov 01; 52(6):330-8. PubMed ID: 25453376
    [Abstract] [Full Text] [Related]

  • 7. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
    Fang DD, Zhang B, Gu Q, Lira M, Xu Q, Sun H, Qian M, Sheng W, Ozeck M, Wang Z, Zhang C, Chen X, Chen KX, Li J, Chen SH, Christensen J, Mao M, Chan CC.
    J Thorac Oncol; 2014 Mar 01; 9(3):285-94. PubMed ID: 24496003
    [Abstract] [Full Text] [Related]

  • 8. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP, Pathi N, Viswanath S, Rathore A, Pathak A, Sud R.
    Indian J Cancer; 2017 Mar 01; 54(1):203-208. PubMed ID: 29199691
    [Abstract] [Full Text] [Related]

  • 9. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
    Wu SG, Kuo YW, Chang YL, Shih JY, Chen YH, Tsai MF, Yu CJ, Yang CH, Yang PC.
    J Thorac Oncol; 2012 Jan 01; 7(1):98-104. PubMed ID: 22124476
    [Abstract] [Full Text] [Related]

  • 10. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.
    Lancet Oncol; 2014 Sep 01; 15(10):1119-28. PubMed ID: 25153538
    [Abstract] [Full Text] [Related]

  • 11. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, Nakamura T, Matsumoto K, Soda M, Mano H, Uenaka T, Yano S.
    Clin Cancer Res; 2012 Jul 01; 18(13):3592-602. PubMed ID: 22553343
    [Abstract] [Full Text] [Related]

  • 12. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
    Lai Y, Kacal M, Kanony M, Stukan I, Jatta K, Kis L, Norberg E, Vakifahmetoglu-Norberg H, Lewensohn R, Hydbring P, Ekman S.
    Biochem Biophys Res Commun; 2019 Apr 02; 511(2):260-265. PubMed ID: 30791979
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.
    Perez CA, Velez M, Raez LE, Santos ES.
    Lung Cancer; 2014 May 02; 84(2):110-5. PubMed ID: 24598368
    [Abstract] [Full Text] [Related]

  • 17. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
    Kimura H, Nakajima T, Takeuchi K, Soda M, Mano H, Iizasa T, Matsui Y, Yoshino M, Shingyoji M, Itakura M, Itami M, Ikebe D, Yokoi S, Kageyama H, Ohira M, Nakagawara A.
    Lung Cancer; 2012 Jan 02; 75(1):66-72. PubMed ID: 21757253
    [Abstract] [Full Text] [Related]

  • 18. Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib.
    Saraceni C, Li PM, Gainor JF, Stopyra GA, Friedman EL.
    J Thorac Oncol; 2015 Jul 02; 10(7):1116-7. PubMed ID: 26134230
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.